Analysis of growth rate, haematologic, and biochemical parameters of Oncopigs
- PMID: 40463985
- PMCID: PMC12131535
- DOI: 10.1080/23144599.2025.2502711
Analysis of growth rate, haematologic, and biochemical parameters of Oncopigs
Abstract
Pigs are widely used as large animal models in biomedical research due to their physiological and anatomical similarity to humans. The Oncopig, a genetically engineered pig model harbouring Cre recombinase-inducible KRAS G12D and TP53 R167H transgenes, serves as a valuable model for cancer research. This study describes the generation of Oncopig breeding herds and provides a characterization of their growth rate, body size, and physiological parameters, including haematologic, biochemical, and coagulation profiles. Body weight and size were measured in male and female Oncopigs, and blood samples were collected at multiple time points from birth to one year of age. A total of 13 haematologic, 18 biochemical, and 3 coagulation parameters were analysed. While male and female Oncopigs had a comparable growth rate within the first 6 months of age, male Oncopigs exhibited a significantly higher growth rate between 6 and 12 months of age and a higher body weight at 12 months. The mean body weight at 6 months of age was 52.3 kg for male Oncopigs and 48.0 kg for female Oncopigs, while at 11 months of age it was 96.4 kg for male Oncopigs and 71.7 kg for female Oncopigs. Haematologic, biochemical, and coagulation parameters were analysed for Oncopigs under 6 months of age, over 6 months, and collectively for Oncopigs within a year of age. By providing comprehensive data on growth, haematologic, and serum biochemical parameters, this study provides a critical resource for researchers utilizing Oncopigs as large animal models for cancer research and other translational studies.
Keywords: Oncopig; cancer model; growth chart; haematologic and biochemical parameters; large animal model; transgenic pig.
© 2025 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
Conflict of interest statement
L.E. reports grants from United States National Institutes of Health and the Society of Interventional Radiology. C.R.B. reports working for Sus Clinicals. R.C.G. reports grants from United States National Institutes of Health, Guerbet USA LLC, Janssen Research & Development LLC, NeoTherma Oncology, TriSalus Life Sciences, and Sus Clinicals, Inc.; consulting fees from Boston Consulting Group; pending patent for Modeling Oncology on Demand, United States Provisional Patent Application No. 62/813,307; participation on Sus Clinicals, Inc. Scientific Advisory Board; participation on Fluidx Medical Technology Advisory board; participation on Kaveri University Advisory board; and stock or stock options in Sus Clinicals, Inc. L.B.S. and K.M.S. report grants from United States National Institutes of Health, United States Department of Agriculture, Society of Interventional Radiology, Guerbet USA LLC, Janssen Research & Development LLC, TriSalus Life Sciences, and Earli Inc.; work for Sus Clinicals; pending patents for Modeling Oncology on Demand, United States Provisional Patent Application No. 62/813,307, and Patch for Targeted Delivery of an Oncogenic Cargo to a Tissue, United States Patent Application No. 63/306,449. The remaining authors have no conflicts of interest to declare.
Figures
References
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous